Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865782 | 0.98 | LMNA (0.59) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL13861957 | 0.88 | LMNA (0.77) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL589105 | 0.87 | ALDH1A1 (0.57) | LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL18491687 | 0.87 | CTSB (0.67) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL13981972 | 0.85 | KDM4E (0.47) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL3858596 | 0.85 | ALDH1A1 (0.62) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL11192692 | 0.84 | LMNA (0.56) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL9609632 | 0.82 | ALDH1A1 (0.51) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL11196111 | 0.82 | LMNA (0.53) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL6891634 | 0.82 | MEN1 (0.59) | LMNASMN1; SMN2ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-7981880-B2 | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-7981880-B2 | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2167465-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Boehringer Ingelheim International GmbH (DE) | 2010-03-31 | — | — | EP | disclosed |
| EP-1558567-B1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-2016049-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATIVES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| WO-2007122219-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATIVES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1558567-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | disclosed |
| WO-2004039764-A1 | NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | LMNA 1565/4885SMN1; SMN2 995/4885ALDH1A1 243/4885 |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | MCHR2, MCHR1, NPY1R | LMNA 4261/4885SMN1; SMN2 2811/4885ALDH1A1 4267/4885 |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | LMNA 1565/4885SMN1; SMN2 995/4885ALDH1A1 243/4885 |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | MKI67, CCNI, CCNA1 | LMNA 867/4885SMN1; SMN2 1744/4885ALDH1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.